CN102058817B - Tibetan medicinal preparation for treating liver diseases - Google Patents
Tibetan medicinal preparation for treating liver diseases Download PDFInfo
- Publication number
- CN102058817B CN102058817B CN2010105265509A CN201010526550A CN102058817B CN 102058817 B CN102058817 B CN 102058817B CN 2010105265509 A CN2010105265509 A CN 2010105265509A CN 201010526550 A CN201010526550 A CN 201010526550A CN 102058817 B CN102058817 B CN 102058817B
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- liver
- group
- tibetan medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a Tibetan medicinal preparation for treating liver diseases. The Tibetan medicinal preparation for treating the liver diseases consists of the following ingredients in part by weight: 78 to 127 parts of calcite (calcined), 6 to 10 parts of sandalwood, 12 to 20 parts of rosewood heart wood, 8 to 12 parts of Chinese eaglewood, 15 to 25 parts of myrobalan (denucleated), 3 to 5 parts of cardamine, 8 to 12 parts of safflower, 6 to 10 parts of concretio silicea bambusae, 3 to 5 parts of nutmeg, 3 to 5 parts of tsaoko amomum fruit, 12 to 20 parts of emblic leafflower fruit, 9 to 15 parts of seed of pomegranate, 5 to 8 parts of semen holarrhenae, 6 to 10 parts of long pepper extract, 6 to 10 parts of costustoot, 12 to 20 parts of herba dracocephali tangutici, 1.2 to 2 parts of swertia pseudochinensis hara, 8 to 12 parts of Baxiaga, 12 to 20 parts of meconopsis, 6 to 10 parts of herpetospermum pedunculosum, 12 to 20 parts of herba aconiti tangutici, 1.6 to 2.5 parts of in-vitro cultivation bezoar and 0.8 to 1.3 parts of artificial musk. The Tibetan medicinal preparation for treating the liver diseases has obvious curative effects on various diseases. All-natural Tibetan medicinal plants serve as raw materials and no auxiliary materials are added, so the Tibetan medicinal preparation does not have any side effect on a human body, can effectively improve the bioavailability of the human body and can improve human immunity.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly a kind of Tibetan medicinal preparation for the treatment of hepatopathy.
Background technology
The sickness rate of all kinds hepatopathy is higher all over the world at present, especially in developing country.Have every year to surpass hepatalgia, the hepatomegaly that the ill virus hepatitis of 500,000 people, alcoholic hepatitis, liver cirrhosis and hepatocarcinoma cause, treating in the world at present according to estimates liver disease drug has 500 kinds more than, but there is no so far a kind of can really the radical cure.Many hepatopaths develop into nodular cirrhosis owing to can not get effective Drug therapy by hepatalgia and hepatomegaly, and the chronic hepatalgia that has and hepatomegaly continue not heal for a long time, and some chronic hepatalgia and hepatomegaly further worsen into hepatocarcinoma.The hepatitis of liver cancer patient and liver cirrhosis all occur in before the hepatocarcinoma, and the importance of hepatalgia and hepatomegaly treatment is described.It can not only make the hepatopath who loses the labour force recover to some extent, and prevent liver cancer is played active and effective effect, reduces the onset of liver cancer rate.Liver depression and Qi stagnation is one of common syndrome of chronic hepatopathy, how because of feelings will impairing the liver, depression of liver-QI, dredge and to rush down dereliction of duty, but both but perverse and unreasonable manner is violated also qi depression to blood stasis of spleen, and often show as the hepatic region and do swollenly to have a pain, gastral cavity abdomen painful abdominal mass is swollen, poor appetite, weak, can affect the state of an illness and patient to the compliance for the treatment of.Therefore studying true medicable liver disease drug is the task of top priority.2003.03.19, Patent Office of the People's Republic of China discloses the patent of invention (notification number: CN1403099) of a kind of " a kind of Chinese medicine preparation and preparation method for the treatment of hepatopathy " by name, be preparation such as injection, solid preparation, cream and the oral liquid of the medically acceptable various dosage forms that form of 0.3-85% Radix Gentianae active component extract and 15-99.7% pharmaceutic adjuvant, wherein the main active gentiopicroside content in the Radix Gentianae active component extract 〉=90% by percentage by weight.This invention is take Radix Gentianae as main, mainly for prevention and the quality of hepatocarcinoma certain effect arranged.2003.01.01 Patent Office of the People's Republic of China discloses the patent of invention of a kind of by name " medicine for the treatment of hepatopathy ", and (notification number: CN1387908), the weight ratio of its raw material is: Radix Puerariae 25-45, Herba Menthae 20-50, Semen Lablab Album 20-35, Fructus Alpiniae Oxyphyllae 5-25, Pericarpium Citri Reticulatae 10-35, Fructus Amomi 5-30.Fructus Amomi, Semen Lablab Album, Fructus Alpiniae Oxyphyllae, Pericarpium Citri Reticulatae, Radix Puerariae are processed into fine powder, Herba Menthae are soaked produced supernatant, fine powder, supernatant are mixed, add alcohol steep, make the extractum semi-finished product and make again capsule or tablet or electuary or water preparation.This patent is to alcoholic liver injury, fatty liver, and liver cirrhosis and hepatitis have remarkable efficacy.Still lack to improve at present human bioavailability, for the prevention of the hepatopathy of acute and chronic hepatalgia and hepatomegaly and the medicine for the treatment of.
Summary of the invention
The present invention provides a kind of Tibetan medicinal preparation for the treatment of hepatopathy for solving the above-mentioned deficiency of prior art.The present invention's treatment is evident in efficacy by hepatalgia, hepatomegaly that viral hepatitis, alcoholic hepatitis, liver cirrhosis, hepatocarcinoma cause.Simultaneously, the present invention does not add any adjuvant take pure natural Tibetan medicine plant as raw material, to human body without any side effect, and can Effective Raise human bioavailability, improve body immunity.
Technical solution of the present invention is by following Composition of contents:
A kind of Tibetan medicinal preparation for the treatment of hepatopathy is characterized in that: described preparation is comprised of the component of following parts by weight; Mirabilitum crystallina calcine 78～127; Lignum Santali Albi 6～10; Lignum Dalbergiae Odoriferae 12～20; Lignum Aquilariae Resinatum 8～12; Fructus Chebulae's enucleation 15～25; Fructus Amomi Rotundus 3～5; Flos Carthami 8～12; Concretio Silicea Bambusae 6～10; Semen Myristicae 3～5; Fructus Tsaoko 3～5; Fructus Phyllanthi 12～20; Semen Granati 9～15; seed of Cortex Holarrhenae Antidysentericae 5～8; Fructus Piperis Longi 6～10; the Radix Aucklandiae 6～10; tangut dragonhead 12～20; Herba Swertiae bimaculatae 1.2～2; BAXIAGA 8～12; Herba meconopsis integrifoliae 12～20; Herpetospermum caudigerum Wall. 6～10; list loud, high-pitched sound 12～20; In vitro cultured Calculus Bovis 1.6～2.5; the artificial Moschus 0.8～1.3.
Preferably, described preparation is comprised of the component of following parts by weight: Mirabilitum crystallina calcine 100～110; Lignum Santali Albi 8～9; Lignum Dalbergiae Odoriferae 16～18; Lignum Aquilariae Resinatum 10～12; Fructus Chebulae's enucleation 20～22; Fructus Amomi Rotundus 4～5; Flos Carthami 10～12; Concretio Silicea Bambusae 8～9; Semen Myristicae 4～5; Fructus Tsaoko 4～5; Fructus Phyllanthi 16～18; Semen Granati 12～14; seed of Cortex Holarrhenae Antidysentericae 6～8; Fructus Piperis Longi 8～9; the Radix Aucklandiae 8～9; tangut dragonhead 16～18; Herba Swertiae bimaculatae 1.6～1.8; BAXIAGA 10～12; Herba meconopsis integrifoliae 16～18; Herpetospermum caudigerum Wall. 8～9; list loud, high-pitched sound 16～18; In vitro cultured Calculus Bovis 2～2.3; the artificial Moschus 1～1.1.
Optimum, described preparation is comprised of the component of following parts by weight: Mirabilitum crystallina calcine 106, Lignum Santali Albi 8.5, Lignum Dalbergiae Odoriferae 17, Lignum Aquilariae Resinatum 10.6, Fructus Chebulae's enucleation 21.2, Fructus Amomi Rotundus 4.2, Flos Carthami 10.6, Concretio Silicea Bambusae 8.5, Semen Myristicae 4.2, Fructus Tsaoko 4.2, Fructus Phyllanthi 17, Semen Granati 12.7, seed of Cortex Holarrhenae Antidysentericae 6.4, Fructus Piperis Longi 8.5, the Radix Aucklandiae 8.5, tangut dragonhead 17, Herba Swertiae bimaculatae 1.7, BAXIAGA 10.6, Herba meconopsis integrifoliae 17, Herpetospermum caudigerum Wall. 8.5, list loud, high-pitched sound 17, In vitro cultured Calculus Bovis 2.1, artificial Moschus 1.1.
Described preparation is capsule preparations, also can be tablet or granule, dispersant.
Mirabilitum crystallina another name Mirabilitum crystallina of the present invention, water stone, magpie stone, latin name Calcitum, Gypsum Rubrum.Mineral crystal for the Sulfates mineral.The property hot, salty, cold.GUIXIN, stomach, kidney channel.The function clearing away heat-fire, sharp key, detumescence.
Lignum Santali Albi is the heartwood of Santalaceae plant Lignum Santali Albi Santalum album L. trunk.Nature and flavor are hot, warm.Return spleen, stomach, the heart, lung meridian.Function circulation of qi promoting warming middle-JIAO, the appetizing pain relieving.
Lignum Dalbergiae Odoriferae is the dry duramen of leguminous plant Lignum Dalbergiae Odoriferae Dalbergia odorifera T.Chen trunk and root.Nature and flavor are hot, bitter, tepor.Return liver, spleen channel.The function promoting flow of QI and blood, pain relieving, hemostasis.
Lignum Aquilariae Resinatum is the timber that Isolated From Thymelaeaceae Species Lignum Aquilariae Resinatum Aquilaria sinensis (Lour.) Gilg contains resin, and nature and flavor are hot, bitter, tepor.Return spleen, stomach, kidney channel.The function promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, helping inspiration to relieve asthma.Be used for the vexed pain of breast abdominal distention, gastrofrigid vomiting singultus, the QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration.
Fructus Chebulae's (enucleation) is the dry mature fruit of Combretum Racemosum plant Fructus Chebulae Terminalia chebula Retz. or fine hair Fructus Chebulae Terminalia chebula Retz.var.tomentella Kurt..Nature and flavor are bitter, sour, puckery, flat.Return lung, large intestine channel.The function astringing intestine to stop diarrhea is astringed the lung, the pathogenic fire reducing sore-throat relieving.
Fructus Amomi Rotundus is the dry mature fruit of zingiberaceous plant Fructus Amomi Rotundus Amomum kravanh Pierre ex Gagnep. or amomum compactum Soland ex Maton Amomum compactum Soland ex Maton.Nature and flavor are hot, warm.Return lung, spleen, stomach warp.The function removing dampness painful abdominal mass that disappears, circulation of qi promoting warming middle-JIAO, appetite-stimulating indigestion-relieving.Be used for turbid damp obstructing in middle-JIAO, anorexia, hygropyrexia from the beginning of, uncomfortable in chest not hungry, the cold-damp vomiting, chest and abdomen swelling and pain, food stagnation does not disappear.
Flos Carthami is the dried floral of feverfew Flos Carthami Carthamus tinctorius L..Nature and flavor are hot, warm.GUIXIN, Liver Channel.The function promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.
Concretio Silicea Bambusae is the dried block of juice in the bars such as grass Chinese textile bamboo Bambusa textilis MeClure or schizostachyum chinense Rendle Schizostachyum chinese Rendle.Nature and flavor are sweet, cold.GUIXIN, Liver Channel.The function clear heat and eliminate phlegm, cool heart arresting convulsion.
Semen Myristicae is the dry kernel of myristicaceae plant Semen Myristicae Myristica fragrans Houtt..Nature and flavor are hot, warm.Return spleen, stomach, large intestine channel.The function warming middle-JIAO to promote flow of QI, relieving diarrhea with astringents.Be used for Deficiency and coldness of spleen and stomach, incessant chronic diarrhea, abdominal distention, lack of appetite vomiting.
Fructus Tsaoko is the dry mature fruit of zingiberaceous plant Fructus Tsaoko Amomum tsao-ko Crevost et Lemaire.Nature and flavor are hot, warm.Return spleen, stomach warp.Function dampness warming middle-JIAO, the expectorant preventing the attack (or recurrence) of malaria.
Emblic subsystem Tibetan conventional crude drugs.Dry mature fruit for euphorbia plant Fructus Phyllanthi Phyllanthus emblica L..Nature and flavor are sweet, sour, puckery, cool.Attach to the lung and stomach meridians.The function clearing away heat and cooling blood, promoting digestion and invigorating the stomach, the cough-relieving of promoting the production of body fluid.Be used for the heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, xerostomia.
Fructus Piperis Longi is dry near maturation or the mature fruit cluster of Piperaceae plant Fructus Piperis Longi Piper longum L..Nature and flavor are hot, hot.Return stomach, large intestine channel.The function warming spleen and stomach for dispelling cold, therapeutic method to keep the adverse QI flowing downwards pain relieving.
The Radix Aucklandiae is the dry root of feverfew Radix Aucklandiae Aucklandia lappa Decne..Nature and flavor are hot, bitter, warm.Return spleen, stomach, large intestine, three warmers, gallbladder meridian.The function promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion.Be used for breast gastral cavity distending pain, heavy behind the dysentery, food stagnation does not disappear, anorexia.
In vitro cultured Calculus Bovis is made mother solution with the fresh bile of bovid cattle Bos taurus domesticus Gmelin, adds deoxycholic acid, cholic acid, compound calcium bilirubinate etc. and makes.Function clears away heart-fire, and eliminating phlegm is had one's ideas straightened out, cool liver, and endogenous wind stopping is understood.
Artificial Moschus's nature and flavor are hot, warm.GUIXIN, spleen channel.The function refreshment of having one's ideas straightened out, promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain.
Herpetospermum caudigerum Wall. is the dry seed of cucurbitaceous plant Fructus Herpetospermi pedunculosi Herpetospermum pedunculosum (Sex.) Baill..Nature and flavor are cold, hardship.The function removing fire from the liver, gallbladder-heat, detoxifcation.It is sick to be used for the treatment of red bar, hepatopathy, gallbladder disease and dyspepsia.
Seed of Cortex Holarrhenae Antidysentericae is the dry seed of apocynaceae plant tellicherry bark Holarrhena antidysenterica Wall.exA.DC..Nature and flavor are bitter, puckery, and are cold.The function heat clearing away, function of gallbladder promoting, antidiarrheal.It is sick to be used for red bar, liver-gallbladder disease, gastrointestinal calentura, diarrhoea, dysentery.
Tangut dragonhead is the dry aerial parts of labiate tangut dragonhead Dracocephalum tanguticum Maxim..Nature and flavor are sweet, bitter, and are cold.The function removing heat from the liver, hemostasis, the skin ulcer that heals, yellow fluid reducing.Be used for liver, gastric heat, the yellow fluid class is sick, mass formed by blood stasis, and the open sore part does not heal.Seedling is used for ascites, edema.
Semen Granati is the dry seed of Punicaceae plant pomegranate Punica granatum L..Nature and flavor acid, sweet, temperature, profit.Function cures mainly Baconic's sympotoms caused by cold factors, cold syndrome of the stomach disease and all gastropathy.
Herba meconopsis integrifoliae is the full edge Herba meconopsis integrifoliae of bloodroot Meconopsis integrifolia (Maxim.) Franch. and Flos meconopsis quintuplinerviae Meconapsis quintuplinervia Regel, the dry herb of Herba meconopsis integrifoliae Meconopsis lancifolia (Fra-nch.) Franch. that comes into leaves etc.Nature and flavor are sweet, puckery, cold.The function heat clearing away, diuresis, antiinflammatory, pain relieving.
Herba Swertiae bimaculatae is the dry herb of gentianaceae plant Indian Herba Swertiae bimaculatae Swertia chirayita (Roxb.ex Flemi) Karsten.Nature and flavor are bitter, and are cool, rough.Function liver heat removing function of gallbladder promoting moves back all heat.
The list loud, high-pitched sound is the dry herb of ranunculaceae plant Herba Aconiti bonga Aconitum naviculare stapf. or Aconitum tanguticum (Maxim.) Stapf.Nature and flavor are bitter, cool.The function heat-clearing and toxic substances removing.
BAXIAGA is goatweed Herba Veronicae Veronica eriogine H.WinKl. wait the dry herb that belongs to kindred plant together.Nature and flavor are bitter, cold.Function heat clearing away, more skin ulcer, granulation promoting, hemostasis.
Below by the effect of clinical experiment to the existing related preparations of contrast and preparation of the present invention.
1 materials and methods
1.1 case is collected 45 routine patients all from this Out-patient Department, all meets the chronic viral hepatitis B differentiation of symptoms and signs for classification of syndrome standard of hepatopathy Professional Committee of Chinese Chinese medicine association revision in 1991, belongs to Liver depression and Qi stagnation.Primary symptom comprises that hepatic region feeling of distension and oppression, hepatalgia, mood are gloomy, and inferior disease has that gastral cavity abdomen painful abdominal mass is swollen, poor appetite, weak, dizzy, and it is namely diagnosable to have in the primary symptom one and time two persons of disease.Male 32 examples wherein, women 13 examples; 36.6 years old mean age, maximum 55 years old, minimum 21 years old; The state of an illness belongs to slight person's 33 examples, moderate 12 examples.Two groups have comparability.
1.2 set up two groups for the treatment of group 30 examples separately, matched group 15 examples.
1.3 the Therapeutic Method treatment group is given capsule preparations of the present invention, 1 time 4,2 times on the 1st, oral: matched group gives existing preparation secret formula pulvis refrigerans, 1 1g is 2 times on the 1st, oral.Two groups all take 2 weeks as 1 course for the treatment of, timely record when the state of an illness changes was made curative effect when finishing and judge in 2 week.
1.4 observation item and index symptom, liver function.Symptom by without, light, in, scored 0,1,2,3 minutes heavily respectively.
1.5 efficacy assessment standard produce effects: conscious fundamental symptoms disappears, or integration descends more than 80% after the treatment, and liver function is normal again;
Effectively: feel that fundamental symptoms alleviates, or integration descends more than 50% after the treatment, Hepatic function improvement; Invalid: conscious of significant change, liver function is not improved; Worsen: subjective symptoms increases the weight of, and liver function is further unusual.
2 results
2.1 two groups of each symptoms all have obvious improvement behind the symptom treatment, wherein with hepatic region feeling of distension and oppression, hepatalgia, gastral cavity abdomen painful abdominal mass swollen improve more obvious.See table 1 for details.
Table 1 doing well,improving situation
Syndrome integral contrast before and after the table 2 liang group treatment (X ,-s)
2.2 two groups of liver functions have certain improvement after the liver function treatment, but there was no significant difference (P＞0.05) before and after the treatment.See table 3 for details.
Table 3 liang group changes of liver function situation (X-,-S)
2.3 two groups of curative effects are all comparatively satisfied after the curative effect treatment, treatment group produce effects 4 examples, and effective 18 examples, invalid 6 examples worsen 2 examples, total effective rate 73.33% matched group produce effects 2 examples, effective 7 examples, invalid 5 examples worsen 1 example, total effective rate 60%.Compare there was no significant difference (P＞0.05) between two groups.
3 conclusions
Liver depression and Qi stagnation is one of common syndrome of chronic hepatopathy, how because of feelings will impairing the liver, depression of liver-QI, dredge and to rush down dereliction of duty, but both but perverse and unreasonable manner is violated also qi depression to blood stasis of spleen, and often show as the hepatic region and do swollenly to have a pain, gastral cavity abdomen painful abdominal mass is swollen, poor appetite, weak, can affect the state of an illness and patient to the compliance for the treatment of.The present invention is comprised of Mirabilitum crystallina calcine, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Chebulae's enucleation, Fructus Amomi Rotundus, Flos Carthami, Concretio Silicea Bambusae, Semen Myristicae, Fructus Tsaoko, Fructus Phyllanthi, Semen Granati, seed of Cortex Holarrhenae Antidysentericae, Fructus Piperis Longi, the Radix Aucklandiae, tangut dragonhead, Herba Swertiae bimaculatae, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, artificial Moschus etc.Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Amomi Rotundus, Semen Myristicae, Fructus Tsaoko, the Radix Aucklandiae, Fructus Piperis Longi promoting the circulation of QI to relieve pain; Artificial Moschus, Flos Carthami promoting blood circulation to restore menstrual flow, pain relieving; Fructus Phyllanthi, Concretio Silicea Bambusae, Fructus Chebulae's enucleation, Herba Swertiae bimaculatae, tangut dragonhead, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, seed of Cortex Holarrhenae Antidysentericae heat-clearing and toxic substances removing, removing heat from blood heat; The Mirabilitum crystallina calcine is releived liver suddenly; Semen Granati cures mainly Baconic's sympotoms caused by cold factors; Full side share, heat-clearing and toxic substances removing, and removing heat from blood heat is changed Baconic's phlegm-damp, pain relieving.The present invention treats that hepatalgia, hepatomegaly, xanthochromia curative effect that viral hepatitis, alcoholic hepatitis, liver cirrhosis, hepatocarcinoma cause are comparatively satisfied, and aspect taking, patient compliance is better, and as the adjuvant drug of chronic hepatopathy, clinic is applied.
Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Amomi Rotundus, Semen Myristicae, Fructus Tsaoko, the Radix Aucklandiae, Fructus Piperis Longi promoting the circulation of QI to relieve pain among the present invention; Artificial Moschus, Flos Carthami promoting blood circulation to restore menstrual flow, pain relieving; Mirabilitum crystallina calcine, Fructus Phyllanthi, Concretio Silicea Bambusae, Fructus Chebulae's enucleation, Herba Swertiae bimaculatae, tangut dragonhead, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, seed of Cortex Holarrhenae Antidysentericae heat-clearing and toxic substances removing, removing heat from blood heat; Semen Granati cures mainly Baconic's sympotoms caused by cold factors; Full side share, heat-clearing and toxic substances removing, and removing heat from blood heat is changed Baconic's phlegm-damp, pain relieving.The present invention does not add any adjuvant take pure natural Tibetan medicine plant as raw material, to human body without any side effect, and can Effective Raise human bioavailability, improve body immunity.
For showing pharmaceutical preparation of the present invention to the therapeutic effect of hepatopathy, the present invention is done a series of analyses and the contrast experiment is as follows respectively:
The hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the checking of hepatomegaly therapeutical effect:
Hepatalgia and hepatomegaly preventive and therapeutic action to viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma cause can be confirmed in following many-side respectively by zoopery, and particular content and process are as follows:
Laboratory animal: cleaning level wistar male rat, 210 ± 10g (Sichuan Academy of Medical Sciences's medical experiment animal center provides).
Medicine and reagent: 40% carbon tetrachloride rapeseed oil solution (4 ℃ save backup), the analytical pure carbon tetrachloride is produced by Tianjin Chemical Reagents Factory No.1, and rapeseed oil is the edible product oil of commercially available hard-cover human body; 0.9% medical saline is that Kelun Pharm Ind Co., Ltd., Sichuan produces lot number H 51021157; Preparation of the present invention is prepared by preparation research central laboratory; Albumin, globulin, the amino transaminase of alanine, the amino transaminase determination test kit of aspartic acid are provided by Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.; Hyaluronic acid is measured test kit and is provided by Senxiong Science ﹠ Technology Industry Co., Ltd., Shanghai, and all the other reagent are analytical pure, and water is redistilled water.
Experimental technique: rat is divided into matched group (11) after adapting to 5 days at random, model group (75), heavy dose of group (15), small dose group (15); All the other each groups press 5ml/kg subcutaneous injection 40% carbon tetrachloride rapeseed oil solution to the last fortnight except matched group per 2 days morning, and later per 2 days injected dose in the morning changes 3ml/kg into, and matched group is to wait dosage medical saline replacement carbon tetrachloride solution; Each group injection afternoon on the same day, matched group and model group are pressed 0.33ml/kg subcutaneous injection normal saline, large and small dosage group respectively by 0.25,0.125g/kg feeds; Except control group fed tap water and common standard feedstuff, all the other each groups are drunk 10% ethanol water (volume ratio), and the last fortnight high fat Low protein diet (cholesterol of 79.5% Semen Maydis flour+20% Adeps Sus domestica+0.5%) of feeding changes later on and feeds Low protein diet (99.5% Semen Maydis flour+0.5% cholesterol); In the prevention stage, if rat body weight descends 10% than last, then stop to annotate carbon tetrachloride solution once
[6]Extracting at random 14 out from model group behind two first quarter moons changes and feeds the common standard feedstuff and tap water enters outside the treatment stage, all the other rats all stop eating do not cut off the water 18 hours after etherization, extract eyeball and get blood, the centrifugal 10min of 4000r/min behind the room temperature 30min gets each index of determination of serum; Observe liver color and luster, form, liver, spleen are weighed and are made liver section, and the prevention stage finishes.14 rats that model group is extracted out are divided at random two groups again and enter treatment stage, every group 7, the common standard of all feeding feedstuff and tap water were respectively organized rat with the method processing after 18 days by feeding by 0.66ml/kg subcutaneous injection normal saline and 0.25g/kg respectively in per 2 days for treatment matched group and treatment group.
Verification method:
Blood parameters is measured: albumin, globulin, the amino transaminase of aspartic acid, the amino transaminase of alanine, hyaluronic acid enzymatic determination adopt test kit.
Hepatic pathology: get liver Da Ye, 12% formalin is fixed, paraffin embedding, and conventional section, H E dyeing is observed under the light microscopic and is respectively organized the variation of liver tissues of rats pathology.
Data analysis: adopt STATISTICAL 6.0 deal with data, the result is with mean+SD
Expression, relatively with the t check, P＜0.05 is significant difference between group, P＜0.01 is utmost point significant difference.
The result:
One, preparation of the present invention hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the preventive effect of hepatomegaly.
The modeling situation: the prevention stage is compared with matched group when finishing, and model group rat hair color is gloomy, stiff and the movable obvious minimizing of taking action, bradykinesia, appetite, amount of drinking water all obviously reduce, rats'liver, spleen enlargement (table 3), the liver color and luster is dim, surface visible obviously tuberosity and white granular kick, the edge is uneven, and its section is mostly visible pseudolobuli under light microscopic, sinus hepaticus narrows down even disappears, liver rope arrangement disorder.ALT, AST, HA significantly raise (P＜0.01) than matched group, and A, G significantly reduce (P＜0.01) (table 1), liver cirrhosis modeling success.
Table 1 preparation of the present invention on the impact of rat liver function biochemical indicator (
N=7)
Annotate:
aP＜0.05,
bP＜0.01 is compared with model group;
cP＜0.05 is compared with small dose group.
1. blood parameters: with the matched group ratio, model group A, G significantly reduce (P＜0.01), and ALT, AST, HA significantly raise (P＜0.01), and A/G is inverted.Compare with model group, heavy dose of injection group significantly raise A (P＜0.01) and G (P＜0.05) significantly reduce ALT, AST (P＜0.01) and HA (P＜0.05).
Small dose group significantly reduces outside the AST (P＜0.05), and all the other liver function indexes are compared not statistically significant with model group.Large and small dosage group is compared, and heavy dose of group remarkable rising A (P＜0.05), significantly reduces AST (P＜0.05) and ALT (P＜0.05) (table 1).Illustrate that said preparation has certain protecting the liver and anti-hepatomegaly effect to liver cirrhosis, heavy dose of effect is better than low dose.
2. hepatic pathology: liver reads sheet and standards of grading are carried out by West China HSPH of Sichuan University Pathological Staff Room, except 0,1,2,3,4 minute five grade are counted in fibroplasia, all the other indexs are all counted 0,1,2,3 minute four grade, and statistics is respectively organized the rat quantity under the different score values.Obviously visible pseudolobuli is compared with model group under the model group liver section light microscopic, and heavy dose of group steatosis, fibroplasia, hepatic necrosis, sinus hepaticus vascularization degree obviously alleviate, and pseudolobuli appears in none example.Heavy dose of group is except the hepatocyte edema, and all the other each indexs all significantly are lighter than model group.Small dose group only hepatic necrosis obviously is lighter than model group.Compare between two dosage groups, heavy dose of group steatosis, endochylema solidify, fibroplasia, cell infiltration degree obviously are lighter than small dose group (table 2).
Table 2 rat liver section scoring situation (n=7)
Annotate: hepatocyte edema number in three different visuals field of same section par less than 10% 1 minutes, 10-15% meter 2 minutes, 15-20% counted 3 minutes; Can get the steatosis cell quantity on average less than 25% 1 minutes with method, 25-50% meter 2 minutes, 50-75% meter 3 minutes; Endochylema solidifies cell quantity on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; The hepatic necrosis cell quantity is on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; Fibroplasia is visible hypertrophy meter 1 minute, and obviously visible hypertrophy meter is 2 minutes, does not form the meter 3 minutes of whole pseudolobulis in the visual field, and the whole visual field all forms the meter 4 minutes of pseudolobuli.
3. liver, spleen index and mortality rate: compare model group rats'liver, the obvious enlargement of spleen, liver, spleen index significantly higher (P＜0.01) with matched group.Compare heavy dose of group liver index (P＜0.05) significantly on the low side with model group.Two dosage groups are compared, and the liver index of heavy dose of group significantly is lower than small dose group (P＜0.05).Although its excess-three group liver, spleen all have enlargement in various degree except matched group, but heavy dose of group liver enlargement degree obviously is lighter than model group and small dose group (P＜0.05), spleen index is not statistically significant between the three, the prompting splenomegaly may not be subjected to Effects of Traditional Chinese Medicines, mortality rate comparing difference large (table 3) in twos between four groups.
Table 3 respectively organize rats'liver, spleen index and mortality rate (
N=7)
Annotate:
aP＜0.05,
bP＜0.01 is compared with model group;
cP＜0.05 is compared with small dose group.
Two, preparation of the present invention hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the therapeutical effect of hepatomegaly.
1. blood parameters: detected respectively two groups of rat liver function indexes the 5th, 11,18 day for the treatment of.Comparison sheet 1 and table 4 can find out that after the removal cause of disease, matched group and treatment group rat A and G raise than before to some extent, and AST, ALT and HA significantly reduce than before, illustrate that there is certain spontaneous recovery tendency in rat after removing the cause of disease.Compare with the contemporaneity matched group, treatment group significantly reduces (P＜0.05), HA significantly raise (P＜0.05) at the 11st day G, AST, treatment group significantly reduces AST (P＜0.01) and ALT (P＜0.05) in the time of the 18th day, illustrate that preparation of the present invention has certain treatment liver cirrhosis effect, but treatment group A, G and HA continue to raise or reduce in therapeutic process, may be too short owing to treatment time, due to therapeutic effect fails fully to stablize (table 4).
Table 4 preparation of the present invention on the impact of liver function biochemical indicator (
N=7)
Annotate: * P＜0.05, * * P＜0.01 is compared with the contemporaneity matched group.
2. hepatic pathology: liver reads sheet and standards of grading are still carried out by West China HSPH of Sichuan University Pathological Staff Room, and standards of grading are identical with prevention stage 2.3.2 hepatic pathology.Compare with matched group, the apparent color and luster for the treatment of group rat liver is better than matched group mostly, the surface white particles is less, observe under the light microscopic and find, treatment group hepatocyte edema, endochylema solidify, fibroplasia and cell infiltration degree totally are lighter than matched group, but both visible pseudolobulis (table 5) still.
Table 5 rat liver section scoring situation (n=7)
3. liver, spleen index and mortality rate: when treatment stage finished, two groups of rats were all without death; Matched group liver, spleen index are respectively 4.16 ± 0.34,3.94 ± 0.48; Treatment group liver, spleen index are respectively 3.98 ± 0.54,3.16 ± 0.21; Although treatment group liver, spleen index be all less than matched group, not statistically significant.
Above result of study shows: hepatalgia and hepatomegaly preventive and therapeutic action that preparation of the present invention causes viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma.
Hepatalgia and hepatomegaly preventive and therapeutic action to viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma cause can be confirmed in following many-side respectively by zoopery, and particular content and process are as follows:
Laboratory animal: 48 of SPF level Balb/c male mices, in 8 ages in week, body weight 20 ± 2g is purchased from Sichuan Academy of Medical Sciences's medical experiment animal center.Experiment is divided into prevention and treats two stages.In the prevention stage, healthy mice is divided into 4 groups at random: 24 of model group, each 8 of negative control group, heavy dose of group, small dose group.Treatment stage will prevent the rear remaining Liver Fibrosis Model mice of stage model group sampling to be divided at random negative control group and medication therapy groups, every group each 8.
Medicine and reagent: Con A specification is that 25mg/ props up, available from Sigma company.Be dissolved in the solution that medical saline is made into 2.5mg/ml during experiment.Albumin (Alb), total protein (TP) are measured test kit and are provided by Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.; The amino transaminase (ALT) of alanine, the amino transaminase of aspartic acid (AST) builds up bio-engineering research by Nanjing is provided; Hyaluronic acid (HA) is measured test kit, is provided by Senxiong Science ﹠ Technology Industry Co., Ltd., Shanghai; And preparation of the present invention.
Experimental technique: in the prevention stage, the negative control group mice is pressed the dosage tail vein injection saline of 12.5mg/kg, and all the other each groups wait dosage tail vein injection Con A solution.1 time weekly, continued for 9 weeks.Simultaneously, preparation of the present invention is fed administration by large (0.25g/kg), little (0.125g/kg) dosage group.Negative control group and model group are then pressed the dosage subcutaneous injection normal saline of 6.6ml/kg, per 3 days 1 time, continue for 9 weeks.6 model group mices of sampling after 9 weeks, extract eyeball and get blood, with the centrifugal 10min of 4000r/min, get each index of determination of serum behind the room temperature placement 30min, observe the liver appearance, cut the hepatomegaly leaf, 10% formalin is fixed, paraffin embedding, conventional section, HE dyeing is observed liver histopathology and is changed under the light microscopic.After confirming the modeling success, horse back is in kind processed negative control, large and small dosage is respectively organized mice.
Treatment stage, negative control group mice are pressed the dosage subcutaneous injection normal saline of 6.6ml/kg, and the medication therapy groups mice is fed preparation of the present invention by the dosage of 0.25g/kg, continue 31 days.6 mices of every group of sampling are cooked capillary tube puncture eye socket venous plexus and get blood weekly during this period, and preparation serum is measured indices, dynamically observes the treatment situation of mice.
Verification method:
Blood parameters is measured: albumin, globulin, the amino transaminase of aspartic acid, the amino transaminase of alanine, hyaluronic acid enzymatic determination adopt test kit.
Hepatic pathology: get liver Da Ye, 12% formalin is fixed, paraffin embedding, and conventional section, H E dyeing is observed under the light microscopic and is respectively organized the variation of liver tissues of rats pathology.
Data analysis: adopt STATISTICAL 6.0 deal with data, the result is with mean+SD
Expression, relatively with the t check, P＜0.05 is significant difference between group, P＜0.01 is utmost point significant difference.
The result:
One, preparation of the present invention is to hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the preventive and therapeutic action of hepatomegaly.
The modeling situation: the prevention stage proceeded to after 4 weeks, and model group is compared the obvious inappetence that occurred with feminine gender to group, and chaeta is in disorder, and hair color is gloomy, the phenomenons such as bradykinesia.Take out the liver perusal after the prevention stage finishes and can find that also model group mouse liver color and luster is dim, the edge is uneven.Serum testing result (table 1) display model group ALT, AST, HA is than negative control group all extremely significantly higher (P＜0.01), and G, A/G extremely significantly reduce (P＜0.01).The structure of this explanation Liver Fibrosis Model is successfully.But this model group of albumin was compared the significant difference that expection do not occur during serum detected with negative control group, and estimation is because the albuminous half-life reaches 19 days
[11]Although the model group mice has reduced albuminous synthetic after hepatic injury, synthetic albumin does not divide timely and takes off before the hepatic injury, has caused in the testing result the temporary vacation of model group higher.It is worth mentioning that the albumin synthetic quantity of medicament group is compared higher with model group, negative control group, wherein small dose group has produced significance higher (P＜0.05).This phenomenon explanation preparation of the present invention can improve the albuminous synthesis capability of liver, may have the effect of enhancing human body immunity.
1, blood parameters: compare with model group, the small dose group decapacitation extremely significantly reduces outside the A/G (P＜0.01), can also significantly improve A/G (0.05) and significantly reduce ALT, AST (P＜0.05), but majority parameters all has significant difference (A, ALT, AST, P＜0.05) with negative control group.Heavy dose of group then can significantly reduce G (P＜0.05), ALT, AST (P＜0.01), significantly improves A/G (P＜0.01), and indices all approaches and negative control group (P＞0.05) very much.Compare with small dose group, heavy dose of group significantly reduces ALT, AST (P＜0.05) (table 6).Illustrate that this capsule has certain hepatoprotective effect to liver cirrhosis, and drug effect has dose dependent.
Table 6 preparation of the present invention on the impact of mice liver function indexes (
N=6)
The t check: compare with model group, * P＜0.05, △ P＜0.05 is compared in * * P＜0.01 with negative control, △ △ P＜0.01, large small dose group is compared, ▲ P＜0.05, ▲ ▲ P＜0.01
2. hepatic pathology: the serious edema of model group mouse liver cell, a large amount of hepatic necrosis, steatosis, cell infiltration is serious in the portal area, and obvious fibroplasia appears in regional area.Compare with model group, heavy dose of group necrocytosis, cell infiltration, the situation of fibroplasia disappear substantially, cellular edema, steatosis, the lesion degree of endochylema coagulation is also alleviated greatly.Although small dose group has also alleviated various pathological changes to a certain extent, its effect is far away less than heavy dose group (table 7).This just illustrates that preparation of the present invention can effectively protect hepatocyte, prevents hepatocellular degeneration necrosis.And this effect has dose dependent.Liver is read sheet and standards of grading and is carried out by West China HSPH of Sichuan University Pathological Staff Room, and except 0,1,2,3,4 minute five grade were counted in fibroplasia, all the other indexs were all counted 0,1,2,3 minute four grade.
The standby group of table 7 mouse liver section scoring situation
Annotate: hepatocyte edema number in three different visuals field of same section par less than 10% 1 minutes, 10-15% meter 2 minutes, 15-20% counted 3 minutes; Can get the steatosis cell quantity on average less than 25% 1 minutes with method, 25-50% meter 2 minutes, 50-75% meter 3 minutes; Endochylema solidifies cell quantity on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; The hepatic necrosis cell quantity is on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; Fibroplasia is visible hypertrophy meter 1 minute, and obviously visible hypertrophy meter is 2 minutes, does not form the meter 3 minutes of whole pseudolobulis in the visual field, and the whole visual field all forms the meter 4 minutes of pseudolobuli.
Two, preparation of the present invention is to hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the therapeutical effect of hepatomegaly.
1. blood parameters: in month for the treatment of, two groups of mices have been done 4 blood samples selective examination.The result shows that after the removal cause of disease, the ALT of negative control group, the development trend of HA reduce, and are benign developments.This explanation mice has certain self-healing ability.But nonetheless, compare with the contemporaneity negative control group, medication therapy groups has still embodied the significant difference (table 8) of its healing aspect degree.And, ALT, HA after through 31 days treatment all substantially near normal value.The hepatic injury that the preparation of the present invention that this explanation dosage is 0.25g/kg is induced Con A has certain therapeutic effect.
Table 8 preparation of the present invention on the impact of mice liver function indexes (
N=6)
The t check: matched group is compared with treatment group, P*＜0.05, P**＜0.01
2. hepatic pathology: the om observation result shows that the hepatocyte edema of negative control group and the symptom of endochylema coagulation worsen, and other symptom has the trend of alleviation, but wherein the alleviation situation of the symptom of steatosis and hepatic necrosis is smaller.This phenomenon explanation, mice itself is that certain self-healing ability is arranged.Compare with negative control group, all hepatic lesions indexs of medication therapy groups have improvement in various degree, and part index number has been tending towards normally, and wherein with hepatic necrosis, liver inflammatory cellular infiltration and fibroplasia is (table 9) significantly.This is explanation just, and the immunologic liver injury that preparation of the present invention is induced Con A has certain therapeutic effect, and it can effectively remove downright bad hepatocyte, accelerates the fibrous tissue of degraded hypertrophy, thereby makes the liver of pathological changes be tending towards normal.
Table 9 mouse liver section scoring situation
Above result of study shows: preparation of the present invention is to hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the preventive and therapeutic action of hepatomegaly.
The specific embodiment
Embodiment 1
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina calcine 83.2, Lignum Santali Albi 6.7, Lignum Dalbergiae Odoriferae 13.3, Lignum Aquilariae Resinatum 8.3, Fructus Chebulae's enucleation 16.7, Fructus Amomi Rotundus 3.3, Flos Carthami 8.3, Concretio Silicea Bambusae 6.7, Semen Myristicae 3.3, Fructus Tsaoko 3.3, Fructus Phyllanthi 13.3, Semen Granati 10, seed of Cortex Holarrhenae Antidysentericae 5, Fructus Piperis Longi 6.7, the Radix Aucklandiae 6.7, tangut dragonhead 13.3, Herba Swertiae bimaculatae 1.3, BAXIAGA 8.3, Herba meconopsis integrifoliae 13.3, Herpetospermum caudigerum Wall. 6.7, list loud, high-pitched sound 13.3, In vitro cultured Calculus Bovis 1.7, artificial Moschus 0.8.
Embodiment 2
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina calcine 127, Lignum Santali Albi 10.1, Lignum Dalbergiae Odoriferae 20.3, Lignum Aquilariae Resinatum 12.7, Fructus Chebulae's enucleation 25.4, Fructus Amomi Rotundus 5.1, Flos Carthami 12.7, Concretio Silicea Bambusae 10.1, Semen Myristicae 5.1, Fructus Tsaoko 5.1, Fructus Phyllanthi 20.3, Semen Granati 15.2, seed of Cortex Holarrhenae Antidysentericae 7.6, Fructus Piperis Longi 10.1, the Radix Aucklandiae 10.1, tangut dragonhead 20.3, Herba Swertiae bimaculatae 2, BAXIAGA 12.7, Herba meconopsis integrifoliae 20.3, Herpetospermum caudigerum Wall. 10.1, list loud, high-pitched sound 20.3, In vitro cultured Calculus Bovis 2.5, artificial Moschus 1.3.
Embodiment 3
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina calcine 92.5g, Lignum Santali Albi 7.4g, Lignum Dalbergiae Odoriferae 14.8g, Lignum Aquilariae Resinatum 9.3g, Fructus Chebulae's enucleation 18.5g, Fructus Amomi Rotundus 3.7g, Flos Carthami 9.3g, Concretio Silicea Bambusae 7.4g, Semen Myristicae 3.7g, Fructus Tsaoko 3.7g, Fructus Phyllanthi 14.8g, Semen Granati 11.1g, seed of Cortex Holarrhenae Antidysentericae 5.6g, Fructus Piperis Longi 7.4g, Radix Aucklandiae 7.4g, tangut dragonhead 14.8g, Herba Swertiae bimaculatae 1.5g, BAXIAGA 9.3g, Herba meconopsis integrifoliae 14.8g, Herpetospermum caudigerum Wall. 7.4g, list loud, high-pitched sound 14.8g, In vitro cultured Calculus Bovis 1.85g, artificial Moschus 0.93g.
Embodiment 4
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina calcine 110g, Lignum Santali Albi 8.8g, Lignum Dalbergiae Odoriferae 17.6g, Lignum Aquilariae Resinatum 11g, Fructus Chebulae's enucleation 22g, Fructus Amomi Rotundus 4.4g, Flos Carthami 11g, Concretio Silicea Bambusae 8.8g, Semen Myristicae 4.4g, Fructus Tsaoko 4.4g, Fructus Phyllanthi 17.6g, Semen Granati 13.2g, seed of Cortex Holarrhenae Antidysentericae 6.6g, Fructus Piperis Longi 8.8g, Radix Aucklandiae 8.8g, tangut dragonhead 17.6g, Herba Swertiae bimaculatae 1.76g, BAXIAGA 11g, Herba meconopsis integrifoliae 17.6g, Herpetospermum caudigerum Wall. 8.8g, list loud, high-pitched sound 17.6g, In vitro cultured Calculus Bovis 2.2g, artificial Moschus 1.1g.
Embodiment 5
A kind of Tibetan medicinal preparation for the treatment of hepatopathy is characterized in that: described preparation is made of the component of following parts by weight: Mirabilitum crystallina calcine 106g, Lignum Santali Albi 8.5g, Lignum Dalbergiae Odoriferae 17g, Lignum Aquilariae Resinatum 10.6g, Fructus Chebulae's enucleation 21.2g, Fructus Amomi Rotundus 4.2g, Flos Carthami 10.6g, Concretio Silicea Bambusae 8.5g, Semen Myristicae 4.2g, Fructus Tsaoko 4.2g, Fructus Phyllanthi 17g, Semen Granati 12.7g, seed of Cortex Holarrhenae Antidysentericae 6.4g, Fructus Piperis Longi 8.5g, Radix Aucklandiae 8.5g, tangut dragonhead 17g, Herba Swertiae bimaculatae 1.7g, BAXIAGA 10.6g, Herba meconopsis integrifoliae 17g, Herpetospermum caudigerum Wall. 8.5g, list loud, high-pitched sound 17g, In vitro cultured Calculus Bovis 2.1g, artificial Moschus 1.1g.
Claims (4)
1. Tibetan medicinal preparation for the treatment of hepatopathy, it is characterized in that: described preparation is comprised of the component of following parts by weight: Mirabilitum crystallina calcine 78～127; Lignum Santali Albi 6～10; Lignum Dalbergiae Odoriferae 12～20; Lignum Aquilariae Resinatum 8～12; Fructus Chebulae's enucleation 15～25; Fructus Amomi Rotundus 3～5; Flos Carthami 8～12; Concretio Silicea Bambusae 6～10; Semen Myristicae 3～5; Fructus Tsaoko 3～5; Fructus Phyllanthi 12～20; Semen Granati 9～15; seed of Cortex Holarrhenae Antidysentericae 5～8; Fructus Piperis Longi 6～10; the Radix Aucklandiae 6～10; tangut dragonhead 12～20; Herba Swertiae bimaculatae 1.2～2; BAXIAGA 8～12; Herba meconopsis integrifoliae 12～20; Herpetospermum caudigerum Wall. 6～10; list loud, high-pitched sound 12～20; In vitro cultured Calculus Bovis 1.6～2.5; the artificial Moschus 0.8～1.3.
2. a kind of Tibetan medicinal preparation for the treatment of hepatopathy according to claim 1; it is characterized in that: preferred, described preparation is comprised of the component of following parts by weight: Mirabilitum crystallina calcine 100～110; Lignum Santali Albi 8～9; Lignum Dalbergiae Odoriferae 16～18; Lignum Aquilariae Resinatum 10～12; Fructus Chebulae's enucleation 20～22; Fructus Amomi Rotundus 4～5; Flos Carthami 10～12; Concretio Silicea Bambusae 8～9; Semen Myristicae 4～5; Fructus Tsaoko 4～5; Fructus Phyllanthi 16～18; Semen Granati 12～14; seed of Cortex Holarrhenae Antidysentericae 6～8; Fructus Piperis Longi 8～9; the Radix Aucklandiae 8～9; tangut dragonhead 16～18; Herba Swertiae bimaculatae 1.6～1.8; BAXIAGA 10～12; Herba meconopsis integrifoliae 16～18; Herpetospermum caudigerum Wall. 8～9; list loud, high-pitched sound 16～18; In vitro cultured Calculus Bovis 2～2.3; the artificial Moschus 1～1.1.
3. a kind of Tibetan medicinal preparation for the treatment of hepatopathy according to claim 1; it is characterized in that: optimum, described preparation is comprised of the component of following parts by weight: Mirabilitum crystallina calcine 106; Lignum Santali Albi 8.5; Lignum Dalbergiae Odoriferae 17; Lignum Aquilariae Resinatum 10.6; Fructus Chebulae's enucleation 21.2; Fructus Amomi Rotundus 4.2; Flos Carthami 10.6; Concretio Silicea Bambusae 8.5; Semen Myristicae 4.2; Fructus Tsaoko 4.2; Fructus Phyllanthi 17; Semen Granati 12.7; seed of Cortex Holarrhenae Antidysentericae 6.4; Fructus Piperis Longi 8.5; the Radix Aucklandiae 8.5; tangut dragonhead 17; Herba Swertiae bimaculatae 1.7; BAXIAGA 10.6; Herba meconopsis integrifoliae 17; Herpetospermum caudigerum Wall. 8.5; list loud, high-pitched sound 17; In vitro cultured Calculus Bovis 2.1; the artificial Moschus 1.1.
4. the described a kind of Tibetan medicinal preparation for the treatment of hepatopathy of any one claim according to claim 1～3, it is characterized in that: described preparation is capsule preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105265509A CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105265509A CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058817A CN102058817A (en) | 2011-05-18 |
| CN102058817B true CN102058817B (en) | 2013-01-16 |
Family
ID=43994442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105265509A Expired - Fee Related CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058817B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102441156B (en) * | 2011-12-14 | 2013-06-12 | 多吉 | Traditional Tibetan medicinal composition and preparation method thereof |
| CN102580051B (en) * | 2012-03-28 | 2013-09-04 | 丁世广 | Oral liquid for treating hepatitis A |
| CN102657838B (en) * | 2012-05-31 | 2013-11-06 | 山东阿如拉药物研究开发有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
| CN103040909B (en) * | 2013-01-25 | 2014-04-23 | 西藏福田藏医药研究开发有限公司 | Tibetan medicine composition and application of composition in preparation of products for preventing and treating alcoholic liver diseases |
| CN103877475B (en) * | 2014-04-09 | 2017-01-11 | 山东大学齐鲁医院 | Oral pharmaceutical preparation for treating mania |
| CN104096108B (en) * | 2014-07-18 | 2017-12-22 | 乌苏日乐特 | It is a kind of to treat scorching anaesthetic of painful methylene and preparation method thereof |
| US11806379B2 (en) * | 2015-07-15 | 2023-11-07 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| CN105250898A (en) * | 2015-10-16 | 2016-01-20 | 白玛仁增 | Compound Tibetan medicine with efficacy of detoxification and liver protection |
| CN108201589A (en) * | 2016-12-19 | 2018-06-26 | 浏阳市利美免疫力修复中心有限公司 | A kind of Chinese medicine composition for treating hepatitis |
| CN110123922A (en) * | 2019-06-18 | 2019-08-16 | 甘孜藏族自治州藏医院 | A kind of Tibetan medicine medicament of hemostasis |
| CN112043758A (en) * | 2020-09-25 | 2020-12-08 | 兰科加 | A Chinese medicinal composition for treating liver cirrhosis and hepatic fibrosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243002A (en) * | 1999-06-21 | 2000-02-02 | 久美彭措 | Tbetan medicinal pill for treating liver disease and preparation method thereof |
| CN1283492A (en) * | 2000-08-10 | 2001-02-14 | 朋毛 | Tibetan medicine for treating hepatism and its preparing process |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
| CN1364488A (en) * | 2001-01-12 | 2002-08-21 | 杨孟君 | Nano thirteen ingredient Bonga aconite medicine powder and its preparing method |
-
2010
- 2010-11-01 CN CN2010105265509A patent/CN102058817B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243002A (en) * | 1999-06-21 | 2000-02-02 | 久美彭措 | Tbetan medicinal pill for treating liver disease and preparation method thereof |
| CN1283492A (en) * | 2000-08-10 | 2001-02-14 | 朋毛 | Tibetan medicine for treating hepatism and its preparing process |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
| CN1364488A (en) * | 2001-01-12 | 2002-08-21 | 杨孟君 | Nano thirteen ingredient Bonga aconite medicine powder and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058817A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058817B (en) | Tibetan medicinal preparation for treating liver diseases | |
| CN104068284B (en) | For mixed feed treating gosling plague and preparation method thereof | |
| CN102078473B (en) | Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104799115A (en) | Chicken compound feed and preparation method thereof | |
| CN104367879A (en) | Pharmaceutical composition for chickens' internal lesion caused by overexertion and preparation method of pharmaceutical composition | |
| CN103877247B (en) | Medicine being used for the treatment of decubital ulcer and preparation method thereof | |
| CN103385993B (en) | Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN102068653A (en) | Medicament for preparing Tibetan medicament preparation for treating liver diseases | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN106039196B (en) | A pharmaceutical composition for treating hyperlipidemia | |
| CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN103272147B (en) | Traditional Chinese medicine preparation for curing vomiting of pregnancy | |
| CN103055218A (en) | Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN105213807A (en) | Be used for the treatment of the medicine of type of hyperactivity of fire caused by deficiency of YIN recurrent oral ulceration | |
| CN104906502A (en) | Pharmaceutical composition for treatment of chicken damaged by heat and preparation method thereof | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN104623615A (en) | Medicine for treating asthma | |
| CN103610991B (en) | Medicine being used for the treatment of swine gastric ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130116 Termination date: 20201101 |